This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Research

An Open Trial of Olanzapine in Anorexia Nervosa

Nicole C. Barbarich, BS; Claire W. McConaha, BSN; Jill Gaskill, CRNP; Maria La Via, MD; Guido K. Frank, MD; Sarah Achenbach, BS; Katherine H. Plotnicov, PhD; and Walter H. Kaye, MD

Published: November 1, 2004

Article Abstract

Background: Recent reports raise the possibility that olanzapine can assist weight gain and improve behavioral symptoms during refeeding in anorexia nervosa.

Method: Seventeen DSM-IV anorexia nervosa subjects hospitalized between May 1999 and October 2000 were enrolled in open-label treatment with olanzapine for up to 6 weeks. Baseline weight and symptoms were compared to patients’ status at the end of treatment.

Results: Olanzapine administration was associated with a significant reduction in depression, anxiety, and core eating disorder symptoms, and a significant increase in weight. A comparison with our historical data suggests that subjects in this study had a significantly greater decrease in depression.

Conclusion: These data lend support to the possibility that olanzapine may be useful in treating anorexia nervosa. However, a controlled trial is necessary to demonstrate that olanzapine is efficacious.

Volume: 65

Quick Links:

Continue Reading…

Subscribe to read the entire article


Buy this Article as a PDF